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Th17Treg/Th17 balance plays a critical role in maintaining immune homeostasis of acute graft-versus-host disease
(aGVHD) patients. STAT3 is an important factor involved in the instability of Treg and the promotion of Th17.
HMGB1 is a cytokine mediator of inﬂammation and an important chromatin protein regulating gene transcrip-
tion. In this study, we found that the expressions of HMGB1 and STAT3 were higher in CD4+ T cells of patients
with aGVHD compared with those without aGVHD, and the HMGB1 expression was positively correlated with
the STAT3 expression. Simultaneously, their expressions were positively correlated with the severity of the
aGVHD. We also demonstrated that HMGB1 could regulate the expression of STAT3 by modulation of its DNA
methylation in CD4+ T cells, moreover downregulated HMGB1 in aGVHD CD4+ T cells could change the ratio
of Treg/Th17. These data strongly suggest that HMGB1 plays a crucial role in the regulation of Treg/Th17 and
progression of aGVHD.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is
one of the important measures in the treatment of hematological
disorders, but acute graft-versus-host disease (aGVHD) is a frequent
and unpredictable severe inﬂammatory complication which seriously
endangers patients' life [1–3]. aGVHD is a complex inﬂammatory pro-
cess characterized by exaggerated inﬂammatory responses, during
which the release of numerous proinﬂammatory cytokines promotes
the ability of donor T lymphocytes to attack the host tissues including
the skin, liver, and gastrointestinal tract [4].
Accumulated studies have demonstrated that Th17 cell differentia-
tion accelerates the progression of aGVHD. Polarized Th17 cells can in-
duce lethal aGVHD in mice [5]. Th17-associated cytokines including
IL-17 and IL-23 were markedly increased, and closely related to the oc-
currence and development of aGVHD [6]. By contrast, regulatory T cell
(Treg) plays a key role in the maintenance of self-tolerance in various
autoimmune diseases and alloresponse [7]. Tregs contribute to the tol-
erance acquisition to donor antigen in solid organ transplantations [8]
and protection against the development of fatal aGVHD in a murine
model [9]. Treg percentage and Foxp3 expression were signiﬁcantly
lower in severe aGVHD (grades 3 to 4) and mild aGVHD (grades 1 to
2) patients than in patients without aGVHD (grade 0) and healthya, Hunan 410008, China.
. This is an open access article underdonors [6]. T. Fujioka et al. found that at the second week after HSCT,
patients with aGVHD had sharply lower Treg frequency than those
without aGVHD. And these differences were closely relatedwith the in-
cidence of aGVHD [10]. These provided important evidence that the
balance between Th17 and Treg played a critical role during aGVHD.
Signal transducer and activator of transcription 3 (STAT3) is a mem-
ber of the signal transducers and activators of transcription family
which regulates gene expression involved in cell growth and division,
cell movement, and apoptosis [11]. Uncontrolled STAT3 activation
may lead to a variety of immune-mediated disease status. In response
to the proinﬂammatory cytokine IL-6, activation of STAT3 in combina-
tion with TGF-β leads to increased expression of orphan nuclear recep-
tors RORγ and RORα, signature transcription factors for Th17 cells
[12–14]. Recent study has shown that STAT3 is involved in the inhibi-
tion of iTreg cell polarization and the instability of nTregs during acute
murine graft-versus-host disease [15], suggesting that STAT3 may be
an important regulator of Th17 and Treg cells.
High mobility group box 1 (HMGB1) protein is a DNA binding
protein mainly involved in DNA replication, transcription, repair and
stabilizing nucleosome [16]. Li Y. et al. found that HMGB1 can bind to
Gadd45a, which may contribute to DNA demethylation of CD11a and
CD70 in SLE CD4+ T cells [17]. Enhanced HMGB1 is reported to inhibit
Treg and promote Th17 response during the immune and inﬂammatory
process [18–20]. In the study, we investigated whether HMGB1 is in-
volved in the regulation of abnormal expression of STAT3 in CD4+ T
cells from aGVHD patients. We found that HMGB1 and STAT3the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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expression could be correlated with the severity of the aGVHD. We
also demonstrated that HMGB1 can regulate STAT3 expression bymod-
ulating the methylation of the STAT3 promoter region. Together, our
ﬁndings shed light on novelmolecularmechanisms of STAT3 dysregula-
tion in CD4+ T cells of aGVHD patients.2. Materials and methods
2.1. Subjects
Forty patients who underwent allo-HSCT from HLA-identical sibling
donors at the Center for Hematopoietic Stem Cell Transplantation at
Xiangya Hospital, Central South University were included in this
study. The characteristics of these patients are shown in Table 1. This
study was approved by the human ethics committee of the Central
SouthUniversity XiangyaMedical School, andwritten informed consent
was obtained from all patients. The adoption of conditioning regimen
mainly accord to the disease types and patients' general status. AML
(acute myeloid leukemia) and MDS (myelodysplastic syndrome):
cytarabine (2 g/m2 per day, days−9 to−8), busulfan (3.2 mg/kg per
day, intravenously days−7 to−5), cyclophosphamide (1.8 g/m2 per
day, days−4 to−3), semustine (250mg/m2, day−2). ALL (acute lym-
phocytic leukemia): Total body irradiation (TBI) (5 Gy per day, days−5
to −4), cyclophosphamide (1.8 g/m2 per day, days −3 to −2). CML
(Chronic myeloid leukemia): busulfan (3.2mg/kg per day, intravenous-
ly days−8 to−5), cyclophosphamide (1.8 g/m2 per day, days−4 to
−3), semustine (250 mg/m2, day −2). We use granulocyte colony
stimulating factor (G-CSF) for peripheral blood hematopoietic stem
cell (PBSC) mobilization. The GVHD prophylaxis regimen consisted of
a combination of cyclosporine A (CsA) and short-term methotrexate
(MTX). The dosage of CsAwas 2.5mg/kg/day, i.v. fromday−9. The dos-
age of MTX was 15 mg/m2 administered i.v. on day +1 and 10 mg/m2
on days +3 and +6.
Assessment of aGVHD was based on clinical symptoms in accor-
dance with commonly accepted criteria [21,22].Organ lesions of the
skin, liver, and gastrointestinal tract was staged 1 through 4 for
aGVHD, patients were also assigned a grade of aGVHD (1 through
4) based on overall severity. aGVHD bgrade 2 was treated continuously
according to the prophylaxis regimen. aGVHD ≥grade 2 was treated
withmethylprednisolone (2mg/kg/day), MTX and anti-CD25monoclo-
nal antibody were given to subjects intolerant of or unresponsive to
methylprednisolone.
We analyzed samples from patients at onset of aGVHD (grade 1 to
4) (n = 24) and time-matched samples from patients without aGVHD
(grade 0) (n = 16). Peripheral blood samples were collected as soon
as aGVHD was diagnosed and before therapy was begun.Table 1
Clinical characteristics of patients.
No GVHD GVHD
Number 16 24
Median age 31 35
Sex (female/male) 7/9 8/16
Diagnosis
ALL 8 12
AML 6 9
MDS 1 3
CML 1 0
Acute GVHD grade
1 6
2 7
3 7
4 4
Days to aGVHD onset, median (range) 43 (range: 13–82)2.2. Isolation, culturing and transfection of CD4+ T cells
CD4+ T cells were puriﬁed from 60 ml venous peripheral blood
using human CD4 beads according to protocols provided by the
manufacturer (Miltenyi, Bergisch Gladbach, Germany), and cultured
in human T cell culture medium (Lonza, Walkersville, MD, USA)
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/
streptomycin. CD4+ T cells were transfected using the Human T cell
Nucleofector Kit and Amaxa nucleofector (Lonza, Walkersville, MD,
USA). First, CD4+ T cells were harvested and resuspended in 100 μl
human T cell nucleofector solution, and then the cell suspension
was mixed with either siRNA-HMGB1 or control. The mix was
electrotransfected using nucleofector program V-024 in the Amaxa
nucleofector. The transfected cellswere cultured in human T cell culture
medium and harvested for 48 h.
2.3. RNA extraction and real-time quantitative RT-PCR
Total RNA was isolated from CD4+ T cells using TRIzol Reagent
(Invitrogen, Carlsbad, CA). RNA was reverse transcribed into cDNA
using random primer and SuperScript II reverse transcriptase
(Invitrogen) according to the manufacturer's instructions. Real-time
PCR was performed in triplicate using the SYBR Green Master Mix (ABI
Prism 7500, Foster City, CA). HumanGAPDH genewas used as an endog-
enous control for sample normalization. The fold change was calculated
using the formula 2−ΔΔCt.ΔΔCt= (Cttarget gene− Ctinternal control)sample−
(Cttarget gene− Ctinternal control)control. Primers are listed in Table 2.
2.4. Western blot analysis
CD4+ T cells were lysed in protein lysis buffer containing proteinase
inhibitor (Thermo Pierce). Lysates were centrifuged for 15 min at
14,000 g at 4 °C, and protein concentration was determined by the
Bradford protein assay (Bio-Rad, CA, USA). Proteins were separated by
SDS-PAGE using 8% polyacrylamide gels, and then transferred onto
PVDF blotting membranes (Bio-Rad, CA, USA). Membranes were
blocked with 5% non-fat dry milk in Tris-buffered saline containing
0.1% Tween-20 (TBST) buffer and immunoblottedwith primary antibod-
ies include anti-HMGB1 (Abcam, MA, USA), anti-STAT3 (Cell Signaling,
BSN, USA), and anti-GAPDH (Santa Cruz, CA, USA). Band intensity was
quantiﬁed using Quantity One software (Bio-Rad, CA, USA).
2.5. Genomic DNA extraction and bisulﬁte sequencing
Genomic DNA was isolated from CD4+ T cells using the TIANamp
Genomic DNA Kit (TIANGEN, Beijing, China). Bisulﬁte conversion was
performed using the EpiTect Bisulﬁte Kit (Qiagen, CA, USA). Three CpG
islands within the STAT3 promoter region were ampliﬁed by PCR. The
PCR products were next subcloned into a pGEM-T vector (Promega,
WI, USA). Ten independent clones were sequenced for each of the
ampliﬁed fragments. Primers used were as follows:
5′GTAGAATATTTTATGTATTTTAATTTAG′ (forward1) andTable 2
Primer sequences for real-time PCR.
Forward primer Reverse primer
HMGB1 TTGTCGGGAGGAGCATAAGA GGGCGATACTCAGAGCAGAAG
STAT3 AAGGAGGCGTCACTTTCACT AACTTGGTCTTCAGGTATGGG
RORγt GCTGGTTAGGATGTGCCG GGATGCTTTGGCGATGA
IL17A CAATCCCACGAAATCCAGGATG GGTGGAGATTCCAAGGTGAGG
IL17F TGCTCAAGGAAAGGAAGACA ATGGTGGATGACAGGGGTG
Foxp3 GAGAAGCTGAGTGCCATGCA AGAGCCCTTGTCGGATGAT
CTLA4 CAGACCTGCCATGCCAATTTG GGCCCATATACTTGGAATGGAACA
IL10 TGAGAACAGCTGCACCCACTT TCGGAGATCTCGAAGCATGTTA
TGF-β GGCAGTGGTTGAGCCGTGGA TGTTGGACAGCTGCTCCACCT
GAPDH AAGAGCTACGAGCTGCCTGAC ATGGCCCAGCGGATGAG
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5′ TTTAGTTGTTTTTTTTATTGGTTAGTGG3′ (forward2) and
5′ CCCACCCTACACCCCCTTCACCTATTTC3′ (reverse2);
5′ TTTGGGATTTTGGGGATGTTGTGATGG3′ (forward3) and.
5′ TCCAAAAAAACACAACTATCTCCTAAAA3′ (reverse3).
2.6. Statistical analysis
Results are expressed asmean± SD. Data were analyzed by ANOVA
followed by the unpaired Student's t-test for multiple comparisons. All
analyses were preformed with SPSS 16.0 software. Signiﬁcance was
set at p values ≤ 0.05.
3. Results
3.1. Patients
Among the 40 HSCT patients, 24 presented with aGVHD vs 16 who
did not. Of the 24 patients who developed aGVHD, 6 (25%) were grade
1, 7 (29.2%) were grade 2, 7 (29.2%) were grade 3, and 4(16.6%) were
grade 4. The median day of onset of aGVHD was 43 (range: 13–82). 18
episodes of grades 2 to 4 aGVHDwere treatedwithmethylprednisolone,
and 13 (72.2%) episodes were treated successfully, whereas the 5 epi-
sodes that lacked adequate response to the primary treatment were
treated with intravenous MTX (10 mg per day, 1 to 2 times per week),
anti-CD25 monoclonal antibody. 4 episodes showed improvement, but
the remaining 1 patient had exacerbated GVHD and subsequently died.Fig. 1.HMGB1 and STAT3 expression levels in CD4+T cells frompatientswith aGVHD.A–B: Rela
aGVHD (n= 24) and patients without aGVHD (n= 16) normalized to GAPDH. C: Representati
severe aGVHD (n=24) and patients without aGVHD (n=16). GAPDHwas used for normalizat
normalized by GAPDH. F–G: The correlation between HMGB1 protein levels and STAT3 mRNA3.2. Expression levels of HMGB1 and STAT3 in CD4+ T cells from aGVHD
patients
In the early days, HMGB1 was identiﬁed as a DNA-binding protein
that functions as a structural co-factor critical for proper transcriptional
regulation [23]. STAT3 is an important factor by regulation of the bal-
ance between Treg and Th17 involved in the pathogenesis of aGVHD
[24]. Inhibition of the STAT3 activity could repress the development of
aGVHD [25]. In this part, we investigatedwhether HMGB1was involved
in the regulation mechanism of abnormal expression of STAT3 in CD4+
T cells from aGVHD patients. We measured the mRNA and protein ex-
pression levels of HMGB1 and STAT3 in CD4+ T cells from 24 HSCT pa-
tients with aGVHD and 16 HSCT patients without aGVHD (the purity of
CD4+ T cells from 60ml venous peripheral blood: 96.9%±2.1%, and the
absolute numbers: 3.12± 1.25 × 106). The results from real-time quan-
titative RT-PCR andwestern blot showed that HMGB1 (Fig. 1A, C and D)
and STAT3 (Fig. 1B, C and E) expressions were signiﬁcantly up-
regulated in patients with aGVHD compared with patients without
aGVHD. Furthermore, the expressions of HMGB1 and STAT3 were
even higher in severe aGVHD (grades 3 to 4) patients compared with
that of patients withmild aGVHD (grades 1 to 2).We also did the corre-
lation analysis between HMGB1 and STAT3 expression in CD4+ T cells
from patients with aGVHD. Result showed that the expressions of
HMGB1 and STAT3 were signiﬁcantly positive correlated (Fig. 1F and
G). Together, our results suggest that patients with aGVHD manifest a
high expression of HMGB1 and STAT3 compared to patients without
aGVHD, and their expression could be correlated with the severity of
the aGVHD.tiveHMGB1 (A) and STAT3 (B)mRNA levels in CD4+T cells frompatientswithmild/severe
ve western blotting results for HMGB1 and STAT3 in CD4+ T cells from patients with mild/
ion. D–E: Quantitative analysis of the band intensities for HMGB1 and STAT3 protein levels
/protein levels (r = 0.66, p b 0.01/r = 0.654, p b 0.01, n = 24). (**, p b 0.01).
Fig. 2.DNAmethylation of STAT3 promoter in CD4+T cells frompatientswith aGVHD. A:Diagramdepicting the STAT3promoter region contains threeCpG islands. B: Averagemethylation
status of STAT3 promoter in CD4+ T cells from patients with mild/severe aGVHD (n= 24) and patients without aGVHD (n= 16). C: The correlation betweenmethylation levels of STAT3
promoter and itsmRNA levels (r=−0.525, p b 0.01, n=24). D: The correlation betweenmethylation levels of STAT3 promoter andHMGB1 protein levels (r=−0.559, p b 0.01, n=24).
(**, p b 0.01).
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aGVHD
To investigatewhether the promoter region of STAT3was aberrantly
DNA methylated in CD4+ T cells from patients with aGVHD, we did
bisulfate sequencing analysis for a region (−730 to +770) ﬂanking
the STAT3 promoter, which contains three CpG islands (Fig. 2A). The
STAT3 promoter was found to be signiﬁcantly hypomethylated in
CD4+ T cells from patients with aGVHD as compared with patients
without aGVHD (Fig. 2B), and the methylation of STAT3 was even
lower in severe aGVHD (grades 3 to 4) patients compared with that of
patients with mild aGVHD (grades 1 to 2). Further, we found that the
STAT3 promoter DNA methylation was negatively correlated with its
mRNA level through the correlation analysis (Fig. 2C). In addition, we
found that the HMGB1 protein levels were inversely correlated with
the methylation status of the STAT3 promoter (Fig. 2D). These data
strongly suggest that the abnormally elevated HMGB1 may contribute
to the DNA hypomethylation of the STAT3 promoter in CD4+ T cells of
aGVHD patients.3.4. Downregulation of HMGB1 can reduce STAT3 expression by promoting
its DNA methylation in aGVHD CD4+ T cells
To further demonstrate the impact of HMGB1 on STAT3 expression,
we repress HMGB1 expression by transfection with siRNA-HMGB1 inFig. 3. Assessment of STAT3 promoter DNAmethylation after downregulation of HMGB1 in aGV
with siRNA-HMGB1 or control siRNA in aGVHDCD4+T cells. B–C:Representativewestern blotti
cellswhichwere transfectedwith siRNA-HMGB1or control siRNA.D: Averagemethylation statu
siRNA. (*, p b 0.05), (**, p b 0.01). Data are presented as the mean ± SD of the same experimeCD4+ T cells from aGVHD patients. Real-time quantitative RT-PCR anal-
ysis showed that siRNA-HMGB1 transfection rendered much lower ex-
pression of HMGB1 and STAT3 mRNA in aGVHD CD4+ T cells
(Fig. 3A), and similar results were obtained by western blot analysis
(Fig. 3B and C). Further, bisulfate sequencing analysis revealed DNA
hypermethylation in the STAT3 promoter after transfected with
siRNA-HMGB1 in aGVHD CD4+ T cells (Fig. 3D). Overall, these data sug-
gest that HMGB1 plays a crucial role in the regulation of STAT3 expres-
sion by modulation of its DNA methylation in CD4+ T cells of aGVHD
patients.
3.5. Expression of Th17 and Treg associated genes in aGVHD CD4+ T cells
after downregulation of HMGB1
In order to detect the inﬂuence on Th17 and Treg after downregula-
tion of HMGB1 in aGVHD CD4+ T cells, we assessed the expression of
RORγt, IL17A, IL17F related to Th17 and Foxp3, CTLA4, IL10, and TGF-
β related to Treg by real-time quantitative RT-PCR. We observed de-
creased mRNA level of RORγt, IL17A and IL17F (Fig. 4A), and increased
mRNA level of Foxp3 and CTLA4 (Fig. 4B). There were no signiﬁcant
differences in IL10 and TGF-βmRNA expression (Fig. 4B).
4. Discussion
Acute graft-versus-host disease (aGVHD) is a primary T cell mediat-
ed severe complication of allogeneic hematopoietic stem cellHD CD4+ T cells. A: Measurement of mRNA levels of HMGB1 and STAT3 after transfected
ng results and quantitative analysis of the band intensities forHMGB1and STAT3 inCD4+T
s of STAT3 promoter in CD4+T cellswhichwere transfectedwith siRNA-HMGB1or control
nts performed in three aGVHD patients.
Fig. 4. Expression of Th17 and Treg associated genes in aGVHDCD4+ T cells after downregulation of HMGB1. A:mRNA levels of RORγt, IL17A and IL17F in aGVHDCD4+ T cells after down-
regulation of HMGB1. B: mRNA levels of Foxp3, CTLA4, IL10 and TGF-β in aGVHD CD4+ T cells after downregulation of HMGB1. (**, p b 0.01). Data are presented as themean± SD of the
same experiments performed in three aGVHD patients.
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bidity and mortality due to the damage to target organs including the
skin, liver, and gastrointestinal tract [4].
High-mobility group box 1 (HMGB1), originally described as a non-
histone and highly mobile DNA-binding protein, can regulate proper
transcription as a structural co-factor [28]. HMGB1 polymorphisms are
associated with aGVHD after allogeneic hematopoietic cell transplanta-
tion [29]. HMGB1, as a key mediator of inﬂammation leading to both
acute and chronic organ injury, can directly bind to TLR4 or format com-
plexes with endogenous or exogenous molecules in extracellular or cy-
toplasm space to trigger inﬂammation [30–32]. The HMGB1–IL-23–IL-
17–IL-6–Stat3 axis plays a pivotal role in tumor development in murine
models of melanoma, and blocking any portion of this axis will attenu-
ate melanoma tumor growth [33]. In this study, we found that the
expressions of HMGB1 and STAT3 in CD4+ T cells from patients with
aGVHD are higher compared to patients without aGVHD. And the
HMGB1 expression was positively correlated with the STAT3 expres-
sion. Simultaneously, their expressions were positively correlated with
the severity of the aGVHD. These indicated that HMGB1 may be one of
the main causes of elevated STAT3 in CD4+ T cells from patients with
aGVHD.
Li Y. et al. have elucidated that HMGB1 was involved in the patho-
genesis of lupus by binding to Gadd45a, and leading to DNA demethyl-
ation in CD4+ T cells [17]. In our study, we elucidated that the
abnormally elevated HMGB1 contributes to the DNA hypomethylation
of the STAT3 promoter in CD4+ T cells of aGVHD patients.We also dem-
onstrated that HMGB1 plays a crucial role in the regulation of STAT3 ex-
pression by modulating its DNA methylation in CD4+ T cells of aGVHD
patients.
Th17 cells were characterized by the production of IL-17A, IL-17F,
IL-21, and IL-22 [34], and its associated cytokines IL-21, IL-22, IL-23,
and IL-6 have been reported to play a pivotal role during aGVHD
[35–38]. Studies inmurinemodels showed that Th17 plays a pathogenic
role in aGVHD [39,40]. In humans, some retrospective reports have
shown that circulating and/or tissue localized Th17 cells can be in-
creased in aGVHD [41,42]. The steroid receptor-type nuclear receptor
RORγt is an essential factor for the differentiation of Th17 cells [43],
and the induction of RORγt is dependent on STAT3 [44]. Furthermore,
STAT3 and RORγt could bind to the IL17 promoter directly, and collab-
oratively promote the production of IL-17 [45]. In our study, the expres-
sion of STAT3 was sharply reduced, after downregulation of HMGB1 in
aGVHD CD4+ T cells. And RORγt, IL17A, and IL17F mRNA levels were
signiﬁcantly decreased, which indicated that HMGB1 is pivotal in the
regulation of Th17 in aGVHD.
CD4+CD25+Foxp3+ regulatory T cells (Tregs) contribute to
maintaining and regulating immune tolerance to self-antigens. Treg
cells possess high potency to suppress immune responses mainly by
contact-mediated direct inhibition of effector T cells and secretion of
suppressive cytokines such as IL-10, TGF-b and CTLA4. Accumulatingstudies have demonstrated that the decreasing frequencies of Tregs
are associated with a higher incidence of aGVHD in patients who have
undergone allo-HSCT [46–48]. Foxp3 is a member of the forkhead/
winged-helix family of transcription factors and acts as a “master”
regulator in the development and suppressive function of Tregs. Foxp3
controls Treg functions by inhibiting IL-2 transcription and upregulating
CTLA4 levels [49]. A recent study showed that Foxp3 could form a coop-
erative complex with NF-AT to up-regulate the expression of CTLA4
[50]. Arian Laurence et al. have demonstrated that transcription factor
STAT3 can promote the instability of nTreg cells and limit the generation
of iTreg cells, and Foxp3 expression was increased in STAT3-deﬁcient
naïve CD4+ T cells [15]. Visibly, STAT3 is an important negative regula-
tor in Foxp3 expression and Treg function. From our results, we found
that the elevated HMGB1 contributes to the overexpression of STAT3
in CD4+ T cells of aGVHD patients. In order to assess the inﬂuence on
Tregs after downregulation of HMGB1 in aGVHD CD4+ T cells, we de-
tected the expression of genes related to Treg, including Foxp3, CTLA4,
IL10 and TGF-β. We observed decreased expression of STAT3 and in-
creased mRNA level of Foxp3 and CTLA4. But there were no signiﬁcant
differences in IL10 and TGF-β expression. Therefore, our data suggested
that HMGB1 could restrain Treg function by regulation of STAT3 in
CD4+ T cells of aGVHD patients.
5. Conclusions
In summary, our studies have demonstrated that HMGB1 could reg-
ulate the expression of STAT3 in CD4+ T cells via modulation of its DNA
methylation, and subsequently promote induction of Th17 lymphocytes
and inhibit differentiation of Treg cells, resulting in disease progression
of aGVHD. Thus, HMGB1 may serve as a potential molecular marker
assisting our diagnosis and assessment of aGVHD after allo-HSCT.
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